| __timestamp | Neurocrine Biosciences, Inc. | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 46425000 | 79838000 |
| Thursday, January 1, 2015 | 81491000 | 121816000 |
| Friday, January 1, 2016 | 94291000 | 117633000 |
| Sunday, January 1, 2017 | 121827000 | 117456000 |
| Monday, January 1, 2018 | 160524000 | 171984000 |
| Tuesday, January 1, 2019 | 200000000 | 257452000 |
| Wednesday, January 1, 2020 | 275000000 | 477643000 |
| Friday, January 1, 2021 | 328100000 | 540684000 |
| Saturday, January 1, 2022 | 463800000 | 651496000 |
| Sunday, January 1, 2023 | 565000000 | 666563000 |
| Monday, January 1, 2024 | 731100000 |
Unleashing the power of data
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Neurocrine Biosciences, Inc. and PTC Therapeutics, Inc. have significantly increased their R&D budgets, reflecting their strategic focus on advancing medical breakthroughs.
From 2014 to 2023, Neurocrine Biosciences saw a remarkable increase in R&D expenses, growing nearly 12 times from approximately $46 million to $565 million. Similarly, PTC Therapeutics expanded its R&D budget by over 8 times, reaching around $667 million in 2023. This upward trend underscores the industry's dynamic nature and the relentless pursuit of new therapies.
As these companies continue to invest heavily in R&D, they not only drive innovation but also set the pace for future advancements in biotechnology, promising a healthier tomorrow.
Who Prioritizes Innovation? R&D Spending Compared for Novo Nordisk A/S and PTC Therapeutics, Inc.
Comparing Innovation Spending: Amgen Inc. and Neurocrine Biosciences, Inc.
Research and Development Expenses Breakdown: Takeda Pharmaceutical Company Limited vs PTC Therapeutics, Inc.
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Alkermes plc
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
R&D Insights: How Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG Allocate Funds
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Vericel Corporation
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Neurocrine Biosciences, Inc. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
R&D Spending Showdown: Amneal Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.
R&D Insights: How PTC Therapeutics, Inc. and Xencor, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for PTC Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc.